66 related articles for article (PubMed ID: 17453593)
1. Differential improvement in survival among patients with AIDS after the introduction of HAART.
Couzigou C; Semaille C; Le Strat Y; Pinget R; Pillonel J; Lot F; Cazein F; Vittecoq D; Desenclos JC;
AIDS Care; 2007 Apr; 19(4):523-31. PubMed ID: 17453593
[TBL] [Abstract][Full Text] [Related]
2. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
[TBL] [Abstract][Full Text] [Related]
3. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
[TBL] [Abstract][Full Text] [Related]
4. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.
Cain LE; Cole SR; Chmiel JS; Margolick JB; Rinaldo CR; Detels R
Am J Epidemiol; 2006 Feb; 163(4):310-5. PubMed ID: 16371516
[TBL] [Abstract][Full Text] [Related]
5. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
6. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH; Udoji MA; Barkanic G; Byrne DW; Rebeiro PF; Byram BR; Kheshti A; Carter JD; Graves CR; Raffanti SP; Sterling TR
J Infect Dis; 2007 Oct; 196(7):1044-52. PubMed ID: 17763327
[TBL] [Abstract][Full Text] [Related]
8. Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.
Wang C; Vlahov D; Galai N; Bareta J; Strathdee SA; Nelson KE; Sterling TR
J Infect Dis; 2004 Sep; 190(6):1046-54. PubMed ID: 15319852
[TBL] [Abstract][Full Text] [Related]
9. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
[TBL] [Abstract][Full Text] [Related]
11. Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy.
Szczech LA; Hoover DR; Feldman JG; Cohen MH; Gange SJ; Goozé L; Rubin NR; Young MA; Cai X; Shi Q; Gao W; Anastos K
Clin Infect Dis; 2004 Oct; 39(8):1199-206. PubMed ID: 15486845
[TBL] [Abstract][Full Text] [Related]
12. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Palepu A; Tyndall MW; Chan K; Wood E; Montaner JS; Hogg RS
Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
[TBL] [Abstract][Full Text] [Related]
13. One year survival of HIV-infected veterans with CD4 < 100 cells/mm3: data from a veteran cohort.
Breaux K; Gadde S; Graviss EA; Rodriguez-Barradas MC
AIDS Care; 2010 Jul; 22(7):886-94. PubMed ID: 20635253
[TBL] [Abstract][Full Text] [Related]
14. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
[TBL] [Abstract][Full Text] [Related]
15. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
16. Outpatient pharmacy care and HIV viral load response among patients on HAART.
Castillo E; Palepu A; Beardsell A; Akagi L; Yip B; Montaner JS; Hogg RS
AIDS Care; 2004 May; 16(4):446-57. PubMed ID: 15203413
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001.
Beck EJ; Mandalia S; Gaudreault M; Brewer C; Zowall H; Gilmore N; Klein MB; Lalonde R; Piché A; Hankins CA
AIDS; 2004 Dec; 18(18):2411-8. PubMed ID: 15622317
[TBL] [Abstract][Full Text] [Related]
18. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children.
Sánchez JM; Ramos Amador JT; Fernández de Miguel S; González Tomée MI; Rojo Conejo P; Ferrnado Vivas P; Clemente Vivas J; Ruiz Contreras J; Nogales Espert A
Pediatr Infect Dis J; 2003 Oct; 22(10):863-7. PubMed ID: 14551485
[TBL] [Abstract][Full Text] [Related]
19. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
[TBL] [Abstract][Full Text] [Related]
20. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
